Hana Na

Hana Na

Auto-generated profile, based on publicly available information

Hana Na

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Open access
PDF file
HNHana Na
Hana Na
HTHua Tian
Hua Tian
ZZZhengrong Zhang
Zhengrong Zhang
QLQiang Li
Qiang Li
JYJack Yang
Jack Yang
WQWendy Qiu
Wendy Qiu
Intraperitoneal injection of amylin or its analog reduces Alzheimer’s disease (AD) pathology in the brains. However, self-injecting amylin analogs is difficult for patients due to cognitive deficits. This work aims to study the effects of amylin on the brain could be achieved by oral delivery as some study reported that amylin receptor may be present in the gastrointestinal tract. A 6-week course of oral amylin treatment reduced components of AD pathology, including the levels of amyloid-β, phosphorylated tau, and ionized calcium binding adaptor molecule 1. The treatment reduced active forms of cyclin-dependent kinase 5. Oral amylin treatment led to improvements in social deficit in AD mouse. Using immunofluorescence, we observed the amylin receptor complexed with the calcitonin receptor and receptor activity-modifying proteins in the enteric neurons. The study suggests the potential of the oral delivery of amylin analogs for the treatment of AD and other neurodegenerative diseases through enteric neurons.